Re: Apabetalone’s Positive Impact on COVID-19 in Human Lung Cells Published in Biomedicines
posted on
Apr 20, 2021 02:37PM
Well how about this:
"This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile."